Skip to navigation Skip to content

T-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051112

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised brentuximab vedotin, mogamulizumab and vorinostat for patients with cutaneous T-cell lymphoma (CTCL), and brentuximab vedotin for patients with peripheral T-cell lymphoma (PTCL).

T-Cell lymphoma and listing dates

Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the thymus or bone marrow.

Cutaneous T-cell lymphoma (CTCL) is a specific type of PTCL where the cells attack the skin.

Listing dates:

  • vorinostat - 1 July 2017
  • brentuximab vedotin - 1 April 2019 (CTCL)
  • brentuximab vedotin - 1 September 2021 (PTCL)
  • mogamulizumab - 1 April 2026

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • FAQs from Service Officers
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs